Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 133 entries
View as:

Tolerability and Steady-state Pharmacokinetics of BIA 6-512

Phase: N/A Priority: Normal
NCT ID: NCT03093389 Org: User:
Start: 05/11/05 End: 07/29/05 Due: 07/29/06

Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy

Phase: N/A Priority: Normal
NCT ID: NCT00980746 Org: User:
Start: 11/30/07 End: 11/30/08 Due: 11/30/09

Effect of Opicapone at Steady State on Warfarin Pharmacokinetics

Phase: N/A Priority: Normal
NCT ID: NCT02305030 Org: User:
Start: 03/31/14 End: 05/31/14 Due: 05/31/15

Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine

Phase: N/A Priority: Normal
NCT ID: NCT02284854 Org: User:
Start: 07/31/09 End: 11/30/09 Due: 11/30/10

Effect of Food on BIA 5-1058

Phase: N/A Priority: Normal
NCT ID: NCT04991155 Org: User:
Start: 07/20/15 End: 09/22/15 Due: 09/22/16

The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin

Phase: N/A Priority: Normal
NCT ID: NCT02172742 Org: User:
Start: 05/31/02 End: 07/25/02 Due: 07/25/03

Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone

Phase: N/A Priority: Normal
NCT ID: NCT02305316 Org: User:
Start: 02/28/14 End: 03/31/14 Due: 03/31/15

Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients

Phase: N/A Priority: Normal
NCT ID: NCT01568047 Org: User:
Start: 02/28/10 End: 06/30/10 Due: 06/30/11

Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures

Phase: N/A Priority: Normal
NCT ID: NCT00957684 Org: User:
Start: 07/31/04 End: 02/28/07 Due: 02/28/08

Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg)

Phase: N/A Priority: Normal
NCT ID: NCT02763839 Org: User:
Start: 04/30/01 End: 07/31/01 Due: 07/31/02

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058

Phase: N/A Priority: Normal
NCT ID: NCT03708146 Org: User:
Start: 05/28/18 End: 03/18/19 Due: 03/18/20

Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067

Phase: N/A Priority: Normal
NCT ID: NCT03119194 Org: User:
Start: 01/27/17 End: 04/27/17 Due: 04/27/18

Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease

Phase: N/A Priority: Normal
NCT ID: NCT03959540 Org: User:
Start: 04/28/20 End: 05/11/21 Due: 05/11/22

Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01679002 Org: User:
Start: 10/31/03 End: 12/31/03 Due: 12/31/04

Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy

Phase: N/A Priority: Normal
NCT ID: NCT00957047 Org: User:
Start: 07/31/04 End: 01/31/08 Due: 01/31/09

Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg)

Phase: N/A Priority: Normal
NCT ID: NCT02763852 Org: User:
Start: 04/30/01 End: 07/31/01 Due: 07/31/02

Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics

Phase: N/A Priority: Normal
NCT ID: NCT02169414 Org: User:
Start: 02/28/10 End: 07/31/10 Due: 07/31/11

Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH (Zamicastat)

Phase: N/A Priority: Normal
NCT ID: NCT04316143 Org: User:
Start: 06/03/19 End: 10/20/21 Due: 10/20/22

A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067

Phase: N/A Priority: Normal
NCT ID: NCT01568034 Org: User:
Start: 04/30/09 End: 02/28/10 Due: 02/28/11

Absorption, Distribution, Metabolism and Excretion of BIA 5-1058

Phase: N/A Priority: Normal
NCT ID: NCT04991181 Org: User:
Start: 03/31/17 End: 05/24/17 Due: 05/24/18

Effect of BIA 5-1058 400 mg on Warfarin Pharmacokinetics

Phase: N/A Priority: Normal
NCT ID: NCT04994119 Org: User:
Start: 02/23/18 End: 05/23/18 Due: 05/23/19

A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093

Phase: N/A Priority: Normal
NCT ID: NCT02171234 Org: User:
Start: 02/28/01 End: 06/30/01 Due: 06/30/02

Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization

Phase: N/A Priority: Normal
NCT ID: NCT02283788 Org: User:
Start: 03/31/07 End: 06/30/07 Due: 06/30/08

A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate

Phase: N/A Priority: Normal
NCT ID: NCT02283814 Org: User:
Start: 01/31/07 End: 02/28/07 Due: 02/28/08

Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202

Phase: N/A Priority: Normal
NCT ID: NCT02772627 Org: User:
Start: 09/30/01 End: 12/31/01 Due: 12/31/02